ABO 2102
Alternative Names: ABO-2102Latest Information Update: 08 Oct 2024
At a glance
- Originator Suzhou Abogen Biosciences
- Class Antineoplastics; Cancer vaccines; Immunotherapies; RNA vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Pancreatic cancer
Most Recent Events
- 29 Aug 2024 Preclinical trials in Pancreatic cancer in China (IM)
- 29 Aug 2024 Suzhou Abogen Biosciences plans phase-I trial for Pancreatic cancer (Monotherapy, Combination therapy) in China (IM) in September 2024 (NCT06577532)